• Contract signed with a total minimum order volume of CHF 1 billion over a five-year period from 2025-2029.
• Companies agree to maintain customer confidentiality.

Bachem Group (SIX: BANB) today announced the signing of a further work order for the delivery of large volumes of peptides for a minimum total of CHF 1 billion over a five-year period from 2025-2029, which follows the conclusion of two large volume contracts announced on 20 September 2022.
The companies have agreed not to disclose additional details and respect customer confidentiality.

Bachem is pursuing an investment program across all sites to expand capacity. A modern large-scale facility for the manufacture of peptides and oligonucleotides (Building «K» – TIDES FABrication Plant) with the potential to double the manufacturing capacity at the Bubendorf site. A new site in Switzerland is planned in Eiken (canton of Aargau) and is intended to further strengthen the production network from the end of the decade onward. Bachem is also investing into capacity expansion across its global manufacturing network at sites in Vionnaz (Switzerland), Torrance (USA), Vista (USA) and St. Helens (UK).

Press release on long-term follow-on contract for peptides

in German

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

For more information:

Bachem Holding AG Dr. Daniel Grotzky Head Group Communications Media: media[at]bachem.com Investors: ir[at]bachem.com